CONTEXT: Alemtuzumab, a humanized monoclonal antibody against @entity7638 , is effective in the treatment of early relapsing-remitting @entity15 ( @entity15 ). Common adverse effects include an @entity2763 , infections and @entity792 , including @entity1374 . SETTING: @entity1 from two phase 3 trials (CARE @entity15 1 and 2, n=15) were studied in a clinical research center. @entity1 : Five out of fifteen @entity1 developed severe @entity2743 after a mean of 32 months following the first alemtuzumab treatment. MAIN OUTCOME MEASURES: Thyroid function tests and thyroid antibodies were assessed. In addition, endocrine tests and measurement of antibodies indicative of autoimmunity were performed. RESULTS: Of the five @entity1 developing @entity2743 , four @entity1 were initially treated with antithyroid drugs, whereas the fifth @entity1 had mild and self-limiting @entity1378 . Of the four @entity1 treated with antithyroid drugs, one is currently under medical treatment in a dose-reducing regimen, whereas three @entity1 underwent near-total thyroidectomy 2, 12 and 16 months later. Two @entity1 developed @entity4903 . Pituitary, adrenal and gonadal hormones were normal in all @entity1 . While four out of five @entity1 were positive for several other autoantibodies, none developed other @entity792 . CONCLUSION: Since @entity1669 is common after alemtuzumab treatment for @entity15 , pretreatment screening and careful follow-up may allow for early diagnosis and treatment.

XXXX after treatment with Alemtuzumab for @entity15 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity2743 :: ('MESH:D006111', 'Disease') :: ["Graves' disease"] @entity1669 :: ('MESH:D013967', 'Disease') :: ['autoimmune thyroid disease'] @entity7638 :: ('1043', 'Gene') :: ['CD52'] @entity1378 :: ('MESH:D006980', 'Disease') :: ['hyperthyroidism'] @entity2763 :: ('MESH:D000210', 'Disease') :: ['acute-phase reaction'] @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases'] @entity4903 :: ('MESH:D004700', 'Disease') :: ['endocrine ophthalmopathy'] @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroid disorders']
@entity2743 :: (MESH:D006111,Disease) :: ['Graves' disease']
